Immunitybio (IBRX) Stock
Clinical biotech developing cancer and infectious disease therapies. Here's the price, business snapshot, and what's worth knowing about Immunitybio in August 2026.
ImmunityBio Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. It pursues a pipeline of biologics, engineered cell approaches and vaccine candidates intended to stimulate or modulate the immune system, using viral-vector and cytokine-based platforms. With a market capitalisation of about $2.40 billion, the stock reflects investor expectations about its clinical programmes and potential commercial opportunities. Key value drivers include trial read-outs, regulatory decisions, partnerships and financing. Like most clinical-stage biotechs, it carries higher volatility and binary outcomes — successful trials can materially increase value, while setbacks can lead to sharp declines. Investors should monitor cash runway, R&D spending and pipeline progress. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a qualified financial adviser before acting.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying ImmunityBio's stock, with a target price indicating significant growth potential.
Financial Health
ImmunityBio is successfully generating strong revenue and profits, with impressive cash flow performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical read-outs and regulatory milestones can move the share price significantly, though outcomes are binary and uncertain.
Platform Technology
Viral-vector and cytokine-based approaches aim to enhance immune response; technological promise requires clinical validation.
Funding & Partnerships
Collaborations and capital raises affect runway and commercial prospects, but financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
